A5065017531- Immunotherapy and Immune Responses
- Immune Response and Inflammation
- SARS-CoV-2 and COVID-19 Research
- Influenza Virus Research Studies
- Immune Cell Function and Interaction
- interferon and immune responses
- Respiratory viral infections research
- COVID-19 Clinical Research Studies
- Infection Control and Ventilation
- Monoclonal and Polyclonal Antibodies Research
- Bacterial Infections and Vaccines
- Virus-based gene therapy research
- Heparin-Induced Thrombocytopenia and Thrombosis
- Climate Change and Health Impacts
- RNA Interference and Gene Delivery
- Neutrophil, Myeloperoxidase and Oxidative Mechanisms
- Pneumonia and Respiratory Infections
- Immune cells in cancer
- Thermal Regulation in Medicine
- Immune responses and vaccinations
- Viral Infections and Immunology Research
- Viral Infectious Diseases and Gene Expression in Insects
- CAR-T cell therapy research
- Nitric Oxide and Endothelin Effects
- Travel-related health issues
Icahn School of Medicine at Mount Sinai
2020-2025
Johnson & Johnson (Israel)
2024
Rensselaer Polytechnic Institute
2024
Synairgen (United Kingdom)
2024
Ghent University
2024
University of Maryland, Baltimore
2022
Ghent University Hospital
2022
Hudson Institute of Medical Research
2019-2020
École Normale Supérieure de Lyon
2018-2020
Université Claude Bernard Lyon 1
2019-2020
Abstract The search for vaccines that protect from severe morbidity and mortality because of infection with acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), the virus causes disease 2019 (COVID‐19) is a race against clock virus. Here we describe an amphiphilic imidazoquinoline (IMDQ‐PEG‐CHOL) TLR7/8 adjuvant, consisting conjugated to chain end cholesterol‐poly(ethylene glycol) macromolecular amphiphile. It water‐soluble exhibits massive translocation lymph nodes upon local...
Antagonism of the neonatal Fc receptor through an engineered antibody fragment, such as efgartigimod, results in a decrease immunoglobulin G levels. This approach is being evaluated therapeutic strategy for treatment IgG-mediated autoimmune diseases. Our goal was to evaluate impact mFc-ABDEG, mouse-adapted fragment with mode action highly similar on vaccine-induced protective immune responses against viral infections. Therefore, mouse vaccination models COVID-19 and influenza were employed,...
Abstract Poly(I:C) is a synthetic analogue of dsRNA capable activating both TLR3 and RLRs, such as MDA‐5 RIG‐I, pathogen recognition receptors. While poly(I:C) known to provoke robust type I IFN, III Th1 cytokine response, its therapeutic use vaccine adjuvant limited due vulnerability nucleases poor uptake by immune cells. encapsulated into lipid nanoparticles (LNPs) containing an ionizable cationic that can electrostatically interact with poly(I:C). LNP‐formulated triggered lysosomal...
Antigenically distinct SARS-CoV-2 variants increase the reinfection risk for vaccinated and previously exposed population due to antibody neutralization escape. COVID-19 severity depends on many variables, including host immune responses, which differ depending genetic predisposition. To address this, we perform profiling of female mice with different backgrounds –transgenic K18-hACE2 wild-type 129S1– infected severe B.1.351, 30 days after exposure milder BA.1 or H1N1. Prior infection...
<title>Abstract</title> Squalene-based adjuvants like MF59, and its research alternative AddaVax, induce transient muscle injury, but their mechanisms downstream of injury remain unclear. We show that an AddaVax-adjuvanted quadrivalent inactivated influenza virus vaccine (QIV) intramuscular injection triggers regeneration-like immune processes increases CX3CR1+Ly6C+ macrophages in the inguinal lymph nodes by day 4 post-injection. This leads to a Th2 skewed response with higher levels...
Influenza vaccine effectiveness could be improved by combination with an adjuvant the potential to enhance host-vaccine response both quantitatively and qualitatively. The goal of this study was explore a RIG-I agonist (SDI-nanogel) TLR7/8 (Imidazoquinoline (IMDQ)‐PEG‐Chol) as adjuvants, when co-administered licensed quadrivalent inactivated influenza (QIV), determine role these adjuvants in directing helper T (Th) cell responses for their immunoglobulin (Ig) class switching. Administration...
Abstract Multiple FDA-approved SARS-CoV-2 vaccines currently provide excellent protection against severe disease. Despite this, immunity can wane relatively fast, particularly in the elderly and novel viral variants capable of evading infection- vaccination-induced continue to emerge. Intranasal (IN) vaccination more effectively induces mucosal immune responses than parenteral vaccines, which would improve reduce transmission. Here, we developed a rationally designed IN adjuvant consisting...
Current COVID-19 mRNA vaccines delivered intramuscularly (IM) induce effective systemic immunity, but with suboptimal immunity at mucosal sites, limiting their ability to impart sterilizing immunity. There is strong interest in rerouting immune responses induced the periphery by parenteral vaccination portal entry site of respiratory viruses, such as SARS-CoV-2, vaccination. We previously demonstrated combination adjuvant, NE/IVT, consisting a nanoemulsion (NE) and an RNA-based RIG-I agonist...
Abstract The search for vaccines that protect from severe morbidity and mortality as a result of infection with acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus causes disease 2019 (COVID-19) is race against clock virus. Several vaccine candidates are currently being tested in clinic. Inactivated recombinant protein can be safe options but may require adjuvants to induce robust immune responses efficiently. In this work we describe use novel amphiphilic imidazoquinoline...
Adjuvants can enhance vaccine effectiveness of currently licensed influenza vaccines. We tested vaccination in a mouse model with two adjuvants: Sendai virus derived defective interfering (SDI) RNA, RIG-I agonist, and an amphiphilic imidazoquinoline (IMDQ-PEG-Chol), TLR7/8 adjuvant. The negatively charged SDI RNA was formulated into lipid nanoparticles (LNPs) facilitating the direct delivery agonist to cytosol. have previously IMDQ-PEG-Chol as standalone combination adjuvants for SARS-CoV-2...
Respiratory interventions including noninvasive ventilation, continuous positive airway pressure and high-flow nasal oxygen generated infectious aerosols may increase risk of airborne disease (SARS-CoV-2, influenza virus) transmission to healthcare workers. We developed tested a prototype portable UV-C
Abstract The search for vaccines that protect from severe morbidity and mortality because of infection with acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), the virus causes disease 2019 (COVID‐19) is a race against clock virus. Here we describe an amphiphilic imidazoquinoline (IMDQ‐PEG‐CHOL) TLR7/8 adjuvant, consisting conjugated to chain end cholesterol‐poly(ethylene glycol) macromolecular amphiphile. It water‐soluble exhibits massive translocation lymph nodes upon local...
There are considerable avenues through which currently licensed influenza vaccines could be optimized. We tested vaccination in a mouse model with two adjuvants: Sendai virus-derived defective interfering (SDI) RNA, RIG-I agonist; and an amphiphilic imidazoquinoline (IMDQ-PEG-Chol), TLR7/8 agonist. The negatively charged SDI RNA was formulated into lipid nanoparticles (LNPs) facilitating direct delivery of to the cytosol, where sensing induces inflammatory type I interferon responses....
<title>Abstract</title> Respiratory interventions including noninvasive ventilation, continuous positive airway pressure and high-flow nasal oxygen generated infectious aerosols may increase risk of airborne disease (SARS-CoV-2, influenza virus) transmission to healthcare workers. We developed/tested a prototype portable UV-C<sub>254</sub> device sterilize high flows viral-contaminated air from simulated patient source at airflow rates up 100 l/m. Our consisted central quartz tube surrounded...
Abstract MF59 (AddaVax-like) is a clinically approved nanoemulsion adjuvant with an unclear mechanism of action. Here we introduce novel approach to investigating the role muscle regeneration in adjuvanted vaccine response. We found that AddaVax quadrivalent inactivated flu (QIV) induced Th2 immune response IL-4, -5, and -13 expression lungs 5 days after H1N1 lethal challenge. In contrast, IMDQ-PC (TLR7/8 agonist) Th1 lung higher IgG2a titers. BMDM cultures, unlike require IFNγ co-incubation...
Abstract Multiple FDA-approved SARS-CoV-2 vaccines provide excellent protection against severe disease. Despite this, immunity can wane relatively fast, particularly in the elderly and novel viral variants capable of evading infection- vaccination-induced continue to emerge. Intranasal (IN) vaccination more effectively induces mucosal immune responses than parenteral vaccines, which would improve reduce transmission. Here, we developed a rationally designed IN adjuvant consisting combined...
Abstract Multiple FDA-approved SARS-CoV-2 vaccines have provided excellent protection against severe disease. Despite this, immunity can wane relatively fast, particularly in the elderly and novel viral variants capable of evading infection- vaccination-induced continue to emerge. Furthermore, while these parenteral substantial protection, they been less effective inducing mucosal immune responses which are critical for effectively blocking transmission vaccinated individuals. As most...
Abstract Influenza vaccine effectiveness could be improved by combination with an adjuvant the potential to enhance host-vaccine response both quantitatively and qualitatively. The goal of this study was explore a RIG-I agonist (SDI-nanogel) TLR7/8 (Imidazoquinoline (IMDQ)‐PEG‐Chol) as adjuvants, when co-administered licensed quadrivalent inactivated influenza (QIV), determine role these adjuvants in directing helper T (Th) cell responses for their immunoglobulin (Ig) class switching....
Abstract Influenza vaccine effectiveness could be improved by combination with an adjuvant the potential to enhance host-vaccine response both quantitatively and qualitatively. The goal of this study was explore a RIG-I agonist (SDI-nanogel) TLR7/8 (Imidazoquinoline (IMDQ)‐PEG‐Chol) as adjuvants, when co-administered licensed quadrivalent inactivated influenza (QIV), determine role these adjuvants in directing helper T (Th) cell responses for their immunoglobulin (Ig) class switching....